Treatment of chronic myeloid leukemia with a tyrosine kinase inhibitor (TKI) offers significant improvements over previous treatments in terms of survival and toxicity yet nevertheless is associated with reduced health-related quality of life and very high cost. | Design and rationale for the life after stopping tyrosine kinase inhibitors LAST study a prospective single-group longitudinal study in patients with chronic myeloid leukemia